Repository logo
 
Publication

Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain

2020-12Journal article Open access
Simple item page
dc.contributor.authorPalladino, Claudia
dc.contributor.authorEzeonwumelu, Ifeanyi J.
dc.contributor.authorMaté, Irene
dc.contributor.authorBorrego, Pedro
dc.contributor.authorMartínez-Román, Paula
dc.contributor.authorArca-Lafuente, Sonia
dc.contributor.authorResino, Salvador
dc.contributor.authorTaveira, Nuno
dc.contributor.authorBriz, Verónica
dc.date.accessioned2023-08-31T13:35:52Z
dc.date.available2023-08-31T13:35:52Z
dc.date.issued2020-12
dc.date.updated2023-02-03T16:40:01Z
dc.description.abstractHepatitis C virus (HCV) infection remains a global health problem. Previously, the prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct-acting antiviral (DAA) against the NS5A viral protein was assessed by our group before its introduction into clinical use in Spain. However, the origin, epidemic history, transmission dynamics, diversity and baseline RASs to NS5A direct-acting agents of HCV-GT1a in Spain remain unknown. A nationwide cross-sectional survey of individuals chronically-infected with HCV-G1a and DAAs-naïve was performed. HCV population sequencing, phylogenetic analysis and Bayesian methods were used. GT1a clade II was more prevalent than clade I (82.3% vs. 17.7%; P < 0.001) and older (estimated origin in 1912 vs. 1952). Clade II epidemic is currently declining whereas clade I epidemic has reached equilibrium. A total of 58 single RASs were identified, which account for the moderate level (10%) of baseline resistance observed. When considering the regional data, marked differences were observed, with thirteen regions showing an intermediate level (5–15%) and one a high level (20%) of resistance. Current HCV-GT1a epidemic in Spain is driven by clade I which seem to have different dissemination routes relative to clade II. A moderate level of baseline RASs to NS5A-DAAs with marked differences among regions was observed. Close surveillance of response to treatment with DAAs will be important.pt_PT
dc.description.sponsorshipThe authors thank patients and the Contributing members of the Spanish Group of Chronic Viral Hepatitis (SI1 Appendix) that have participated in this epidemiological survey and the Multidisciplinary Group of Viral Coinfection HIV/Hepatitis (COVIHEP). The Instituto de Salud Carlos III (ISCIII) provided financial support by the Grant (CP13/00098, PI15CIII/00031 and PI18CIII/00020 to VB). CP is financed by national funds via FCT through Norma Transitória—DL57/2016/CP1376/CT0004.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPalladino C, Ezeonwumelu IJ, Mate-Cano I, Borrego P, Martínez-Román P, Arca-Lafuente S, et al. Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Sci Rep [Internet]. 3 de agosto de 2020;10(1):13024. Disponível em: https://www.nature.com/articles/s41598-020-69692-7pt_PT
dc.identifier.doi10.1038/s41598-020-69692-7pt_PT
dc.identifier.slugcv-prod-2344587
dc.identifier.urihttp://hdl.handle.net/10451/59104
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.nature.com/articles/s41598-020-69692-7pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleEpidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spainpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage13024pt_PT
oaire.citation.titleScientific Reportspt_PT
oaire.citation.volume10pt_PT
person.familyNamePalladino
person.familyNameEzeonwumelu
person.familyNameMaté
person.familyNameBorrego
person.familyNameArca de Lafuente
person.familyNameResino
person.familyNameTaveira
person.familyNameBriz
person.givenNameClaudia
person.givenNameIfeanyi
person.givenNameIrene
person.givenNamePedro
person.givenNameSonia
person.givenNameSalvador
person.givenNameNuno
person.givenNameVerónica
person.identifier1927668
person.identifier2933883
person.identifier407901
person.identifier.ciencia-id721D-6851-20D5
person.identifier.ciencia-idA71C-0177-722F
person.identifier.ciencia-id7111-3383-A926
person.identifier.orcid0000-0002-8148-0928
person.identifier.orcid0000-0003-4007-2212
person.identifier.orcid0000-0002-9045-9581
person.identifier.orcid0000-0002-1949-9484
person.identifier.orcid0000-0003-4750-0988
person.identifier.orcid0000-0001-8783-0450
person.identifier.orcid0000-0003-0176-5585
person.identifier.orcid0000-0003-2297-5098
person.identifier.ridP-9428-2017
person.identifier.ridH-6968-2013
person.identifier.ridA-7807-2019
person.identifier.ridT-4183-2017
person.identifier.scopus-author-id57203432749
person.identifier.scopus-author-id25225039400
person.identifier.scopus-author-id9332849600
rcaap.cv.cienciaid721D-6851-20D5 | Claudia Palladino
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication96b2385b-89f4-428a-9ab2-6fdb5514541b
relation.isAuthorOfPublication124ca7f9-fbba-4c7a-a77b-ecda48de1bb0
relation.isAuthorOfPublication3145c0e5-1ca2-4bdf-b103-9e79218b07cd
relation.isAuthorOfPublication64f9a682-4d1d-4bc3-8854-c6673527f871
relation.isAuthorOfPublicationc082ff9e-3d28-42ce-b50a-b23d5a4417a2
relation.isAuthorOfPublicationa428ce68-f89c-4f34-af69-04b11f8717ca
relation.isAuthorOfPublicationd62b22f8-7ce6-4bb2-ac55-2117707f6612
relation.isAuthorOfPublication4612acdd-e150-40d9-9989-a372cfee3499
relation.isAuthorOfPublication.latestForDiscoverya428ce68-f89c-4f34-af69-04b11f8717ca

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2020_NS5A_HCV_Sci.Rep_Palladino.pdf
Size:
2.16 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FF - CiênciaVitae - Faculdade de Farmácia